Key facts
- It has raised $7.2M; the latest was Early Stage VC in May 2025.
- Notable investors include Lenovo Capital and Incubator Group, Legend Star, Hangzhou Capital, Hangzhou Xihu Industry Fund Management.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for CarbonSilicon
- ·The full record, as it builds
Funding rounds
No funding rounds for CarbonSilicon are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CarbonSilicon
Provider of artificial intelligence infrastructure and services in the field of new drug research and development. The company has established a one-stop new drug discovery SaaS platform DrugFlow. The platform includes modules such as target discovery, virtual screening, lead compound optimization, and druggability prediction, enabling pharmaceutical chemists to find potential drug molecules more efficiently and conveniently.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2021
- Website
- drugflow.com/
- Ownership
- Privately Held (backing)
CarbonSilicon doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CarbonSilicon shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CarbonSilicon in its N-PORT filings yet. We sweep new filings monthly.